Does Diabetes Mellitus Play a Role in Restenosis and Patency Rates Following Lower Extremity Peripheral Arterial Revascularization? A Critical Overview

Annals of Vascular Surgery

Volumn 22, Issue 3, 2008, Pages 481-491

  Paraskevas, Kosmas I ^a   Baker, Daryll M ^a   Pompella, Alfonso ^b   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITINOL; RAPAMYCIN;

AMPUTATION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG ELUTING STENT; EXTERNAL BEAM RADIOTHERAPY; GRAFT PATENCY; HUMAN; IN-STENT RESTENOSIS; MORTALITY; NITINOL STENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; REVIEW; SIROLIMUS ELUTING STENT;

AMPUTATION; CARDIOVASCULAR AGENTS; CONSTRICTION, PATHOLOGIC; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; LOWER EXTREMITY; PERIPHERAL VASCULAR DISEASES; RADIOTHERAPY; RECURRENCE; TREATMENT OUTCOME; VASCULAR PATENCY; VASCULAR SURGICAL PROCEDURES;

EID: 42749086289     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2007.12.012     Document Type: Review

References (153)

1. Weiss J.S., and Sumpio B.E. Review of prevalence and outcome of vascular disease in patients with diabetes mellitus. Eur J Vasc Endovasc Surg 31 (2006) 143-150
2. Pyorala K., Laakso M., and Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3 (1987) 463-524
3. Donahue R.P., and Orchard T.J. Diabetes mellitus and macrovascular complications. An epidemiological perspective. Diabetes Care 15 (1992) 1141-1155
4. Brand F.N., Abbott R.D., and Kannel W.B. Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study. Diabetes 38 (1989) 504-509
5. Uusitupa M.I., Niskanen L.K., Siitonen O., et al. 5-year incidence of atherosclerotic renovascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 82 (1990) 27-36
6. Jude E.B., Oyibo S.O., Chalmers N., et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 24 (2001) 1433-1437
7. Bendermacher B.L., Willigendael E.M., Teijink J.A., et al. Medical management of peripheral arterial disease. J Thromb Haemost 3 (2005) 1628-1637
8. Alnaeb M.E., Alobaid N., Seifalian A.M., et al. Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg 20 (2006) 696-705
9. Daskalopoulou S.S., Athyros V.G., Hamilton G., et al. Lipid-lowering therapy in patients with peripheral arterial disease. J Cardiovasc Pharmacol Ther 10 (2005) 145-147
10. Dean S.M. Pharmacologic treatment for intermittent claudication. Vasc Med 7 (2002) 301-309
11. Youssef M., Gupta P., Mikhailidis D.P., et al. Risk modification in patients with peripheral arterial disease: a retrospective survey. Angiology 56 (2005) 279-287
12. Jagroop I.A., Matsagas M.I., Geroulakos G., et al. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 15 (2004) 117-125
13. De Sanctis J.T. Percutaneous interventions for lower extremity peripheral vascular disease. Am Fam Physician 64 (2001) 1965-1972
14. Goessens B.M., van der Graaf Y., Olijhoek J.K., et al. SMART Study Group. The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg 45 (2007) 47-54
15. Ballard J.L., and Mills J.L. Surgical management of critical limb ischemia. Tech Vasc Interv Radiol 8 (2005) 169-174
16. Sontheimer D.L. Peripheral vascular disease: diagnosis and management. Am Fam Physician 73 (2006) 1971-1976
17. Henry M., Rath P.C., Klonaris C., et al. Peripheral vascular diseases: an update on endovascular therapy. Indian Heart J 57 (2005) 747-766
18. Alobaid N., Alnaeb M.E., Sales K.M., et al. Endothelial progenitor cells and their potential clinical applications in peripheral arterial disease. Endothelium 12 (2005) 243-250
19. Hughes G.C., and Annex B.H. Angiogenic therapy for coronary artery and peripheral arterial disease. Expert Rev Cardiovasc Ther 3 (2005) 521-535
20. Paraskevas K.I., and Mikhailidis D.P. Angiogenesis: a promising treatment option for peripheral arterial disease. Curr Vasc Pharmacol (2008) (in press)
21. Roller R.E., Schnedl W.J., and Korninger C. Predicting the risk of restenosis after angioplasty in patients with peripheral arterial disease. Clin Lab 47 (2001) 555-559
22. Cheshire N.J., Wolfe J.H., Barradas M.A., et al. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis. Eur J Vasc Endovasc Surg 11 (1996) 479-486
23. Martin E.C., Katzen B.T., Benenati J.F., et al. Multicenter trial of the wallstent in the iliac and femoral arteries. J Vasc Interv Radiol 6 (1995) 843-849
24. Sabeti S., Mlekusch W., Amighi J., et al. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther 12 (2005) 6-12
25. Wakhloo A.K., Tio F.O., Lieber B.B., et al. Self-expanding nitinol stents in canine vertebral arteries: hemodynamics and tissue response. AJNR Am J Neuroradiol 16 (1995) 1043-1051
26. Laxdal E., Eide G.E., Wirsching J., et al. Homocysteine levels, haemostatic risk factors and patency rates after endovascular treatment of the above-knee femoro-popliteal artery. Eur J Vasc Endovasc Surg 28 (2004) 410-417
27. Kalra M., Gloviczki P., Bower T.C., et al. Limb salvage after successful pedal bypass grafting is associated with improved long-term survival. J Vasc Surg 33 (2001) 6-16
28. Dandona P., and Aljada A. Advances in diabetes for the millennium: diabetes and the endothelium. MedGenMed 6 3 Suppl (2004) 6
29. Steinberg H.O., Brechtel G., Johnson A., et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94 (1994) 1172-1179
30. Sydow K., Mondon C.E., and Cooke J.P. Insulin resistance: a potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc Med 10 Suppl. 1 (2005) S35-S43
31. Ding Y., Vaziri N.D., Coulson R., et al. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am J Physiol Endocrinol Metab 279 (2000) E11-E17
32. Johnstone M.T., Creager S.J., Scales K.M., et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88 (1993) 2510-2516
33. Williams S.B., Cusco J.A., Roddy M.A., et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27 (1996) 567-574
34. Mikhailidis D.P., Mikhailidis A.M., Barradas M.A., et al. Effect of nonesterified fatty acids on the stability of prostacyclin activity. Metabolism 32 (1983) 717-721
35. Dandona P., Mikhailidis D.P., and Jeremy J.Y. Prostacyclin release in vivo. Lancet 1 (1983) 823-824
36. Jeremy J.Y., Mikhailidis D.P., and Dandona P. Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes 32 (1983) 217-221
37. Park J.Y., Takahara N., Gabriele A., et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 49 (2000) 1239-1248
38. Jagroop I.A., Berwanger C.S., Stansby G., et al. Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs. Int Angiol 18 (1999) 77-79
39. Mangiafico R.A., Malatino L.S., Santonocito M., et al. Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs. Int Angiol 17 (1998) 97-102
40. Kalogeropoulou K., Mortzos G., Migdalis I., et al. Carotid atherosclerosis in type 2 diabetes mellitus: potential role of endothelin-1, lipoperoxides, and prostacyclin. Angiology 53 (2002) 279-285
41. Henry R.M., Kostense P.J., Spijkerman A.M., et al. Hoorn Study. Arterial stiffness increased with deteriorating glucose tolerance status: the Hoorn Study. Circulation 107 (2003) 2089-2095
42. Zieman S.J., Melenovsky V., and Kass D.A. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 25 (2005) 932-943
43. Safar M.E., Levy B.I., and Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107 (2003) 2864-2869
44. Cruickshank K., Riste L., Anderson S.G., et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation 106 (2002) 2085-2090
45. Laurent S., Boutouyrie P., Asmar R., et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37 (2001) 1236-1241
46. Koltai K., Feher G., Kesmarky G., et al. The effect of blood glucose levels on hemorheological parameters, platelet activation and aggregation in oral glucose tolerance tests. Clin Hemorheol Microcirc 35 (2006) 517-525
47. Robless P.A., Okonko D., Lintott P., et al. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 25 (2003) 16-22
48. Matsagas M.I., Geroulakos G., and Mikhailidis D.P. The role of platelets in peripheral arterial disease: therapeutic implications. Ann Vasc Surg 16 (2002) 246-258
49. Muruganandam A., and Mutus B. Isolation of nitric oxide synthase from human platelets. Biochim Biophys Acta 1200 (1994) 1-6
50. Radomski M.W., Palmer R.M., and Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2 (1987) 1057-1058
51. Komarov A., Panchenko E., Dobrovolsky A., et al. D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. Eur Heart J 23 (2002) 1309-1316
52. Robless P., Mikhailidis D.P., and Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 88 (2001) 787-800
53. Dandona P. Endothelium, inflammation, and diabetes. Curr Diab Rep 2 (2002) 311-315
54. Anfossi G., and Trovati M. Pathophysiology of platelet resistance to anti-aggregating agents in insulin resistance and type 2 diabetes: implications for anti-aggregating therapy. Cardiovasc Hematol Agents Med Chem 4 (2006) 111-128
55. Lim H.S., MacFadyen R.J., Bakris G., et al. The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension management. Curr Pharm Des 12 (2006) 1567-1579
56. Kakafika A.I., Liberopoulos E.N., Karagiannis A., et al. Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol 4 (2006) 175-183
57. McGill J.B., Schneider D.J., Arfken C.L., et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43 (1994) 104-109
58. Stegenga M.E., van der Crabben S.N., Levi M., et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 55 (2006) 1807-1812
59. Pandolfi A., Giaccari A., Cilli C., et al. Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type I in the rat. Acta Diabetol 38 (2001) 71-76
60. Banga J.D. Coagulation and fibrinolysis in diabetes. Semin Vasc Med 2 (2002) 75-86
61. Nilsson J., Jovinge S., Niemann A., et al. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 18 (1998) 1199-1202
62. Yudkin J.S., Stehouwer C.D., Emeis J.J., et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 19 (1999) 972-978
63. Festa A., D'Agostino Jr. R., Howard G., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
64. Temelkova-Kurktschiev T., Siegert G., Bergmann S., et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 51 (2002) 743-749
65. Tzoulaki I., Murray G.D., Lee A.J., et al. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J 28 (2007) 354-362
66. Brevetti G., Schiano V., Sirico G., et al. Metabolic syndrome in peripheral arterial disease: relationship with severity of peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity. J Vasc Surg 44 (2006) 101-107
67. McDermott M.M., Liu K., Guralnik J.M., et al. Functional decline in patients with and without peripheral arterial disease: predictive value of annual changes in levels of C-reactive protein and D-dimer. J Gerontol A Biol Sci Med Sci 61 (2006) 374-379
68. Wahlgren C.M., Sten-Linder M., Egberg N., et al. The role of coagulation and inflammation after angioplasty in patients with peripheral arterial disease. Cardiovasc Intervent Radiol 29 (2006) 530-535
69. Prasad D. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 24 (2006) 33-50
70. Rumble J.R., Cooper M.E., Soulis T., et al. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest 99 (1997) 1016-1027
71. Vranes D., Cooper M.E., and Dilley R.J. Cellular mechanisms of diabetic vascular hypertrophy. Microvasc Res 57 (1999) 8-18
72. Gilbert R.E., Rumble J.R., Cao Z., et al. Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. Circ Res 86 (2000) 158-165
73. Song W., and Ergul A. Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size. Cardiovasc Diabetol 5 (2006) 3
74. Harris A.K., Hutchinson J.R., Sachidanandam K., et al. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes 54 (2005) 2638-2644
75. Melliere D., Berrahal D., Desgranges P., et al. Influence of diabetes on revascularization procedures of the aorta and lower limb arteries: early results. Eur J Vasc Endovasc Surg 17 (1999) 438-441
76. Capek P., McLean G.K., and Berkowitz H.D. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation 83 2 Suppl. (1991) I70-I80
77. Laxdal E., Jenssen G.L., Pedersen G., et al. Subintimal angioplasty as treatment of femoropopliteal artery occlusions. Eur J Vasc Endovasc Surg 25 (2003) 578-582
78. Wolfle K.D., Bruijnen H., Loeprecht H., et al. Graft patency and clinical outcome of femorodistal arterial reconstruction in diabetic and non-diabetic patients: results of a multicentre comparative analysis. Eur J Vasc Endovasc Surg 25 (2003) 229-234
79. London N.J., Varty K., Sayers R.D., et al. Percutaneous transluminal angioplasty for lower-limb critical ischemia. Br J Surg 82 (1995) 1232-1235
80. Faglia E., Dalla Paola L., Clerici G., et al. Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. Eur J Vasc Endovasc Surg 29 (2005) 620-627
81. Varty K., Nydahl S., Butterworth P., et al. Changes in the management of critical limb ischaemia. Br J Surg 83 (1996) 953-956
82. Salas C.A., Adam D.J., Papavassiliou V.G., et al. Percutaneous transluminal angioplasty for critical limb ischaemia in octogenarians and nonagenarians. Eur J Vasc Endovasc Surg 28 (2004) 142-145
83. Bolia A., Miles K.A., Brennan J., et al. Percutaneous transluminal angioplasty of occlusions of the femoral and popliteal arteries by subintimal dissection. Cardiovasc Intervent Radiol 13 (1990) 357-363
84. London N.J., Srinivasan R., Naylor A.R., et al. Subintimal angioplasty of femoropopliteal artery occlusions: the long-term results. Eur J Vasc Surg 8 (1994) 148-155
85. Vraux H., Hammer F., Verhelst R., et al. Subintimal angioplasty of tibial vessel occlusions in the treatment of critical limb ischaemia: mid-term results. Eur J Vasc Endovasc Surg 20 (2000) 441-446
86. Karacagil S., Almgren B., Bowald S., et al. Comparative analysis of patency, limb salvage and survival in diabetic and non-diabetic patients undergoing infrainguinal bypass surgery. Diabet Med 12 (1995) 537-541
87. Stirnemann P., Wursten H.U., and Krebs T. Long-term results after infrainguinal arterial reconstruction in patients with type 2 diabetes mellitus and without diabetes mellitus. Dtsch Med Wochenschr 116 (1991) 1175-1179
88. Luther M., and Lepantalo M. Femorotibial reconstructions for chronic critical leg ischaemia: influence on outcome by diabetes, gender and age. Eur J Vasc Endovasc Surg 13 (1997) 569-577
89. Kalman P.G., and Johnston K.W. Predictors of long-term patient survival after in situ vein leg bypass. J Vasc Surg 25 (1997) 899-904
90. Taylor Jr. L.M., Edwards J.M., and Porter J.M. Present status of reversed vein bypass grafting: five-year results of a modern series. J Vasc Surg 11 (1990) 193-205
91. da Silva A.F., Desgranges P., Holdsworth J., et al. The management and outcome of critical limb ischaemia in diabetic patients: results of a national survey. Audit Committee of the Vascular Surgical Society of Great Britain and Ireland. Diabet Med 13 (1996) 726-728
92. Davies A.H., Cole S.E., Magee T.R., et al. The effect of diabetes mellitus on the outcome of angioplasty for lower limb ischaemia. Diabet Med 9 (1992) 480-481
93. Akbari C.M., Pomposelli Jr. F.B., Gibbons G.W., et al. Lower extremity revascularization in diabetes: late observations. Arch Surg 135 (2000) 452-456
94. Soder H.K., Manninen H.I., Jaakkola P., et al. Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: angiographic and clinical results. J Vasc Interv Radiol 11 (2000) 1021-1031
95. Dorweiler B., Neufang A., Schmiedt W., et al. Pedal arterial bypass for limb salvage in patients with diabetes mellitus. Eur J Vasc Endovasc Surg 24 (2002) 309-313
96. Lazaris A.M., Tsiamis A.C., Fishwick G., et al. Clinical outcome of primary infrainguinal subintimal angioplasty in diabetic patients with critical lower limb ischemia. J Endovasc Ther 11 (2004) 447-453
97. Nasr M.K., McCarthy R.J., Hardman J., et al. The increasing role of percutaneous transluminal angioplasty in the primary management of critical limb ischaemia. Eur J Vasc Endovasc Surg 23 (2002) 398-403
98. Awad S., Karkos C.D., Serrachino-Inglott F., et al. The impact of diabetes on current revascularisation practice and clinical outcome in patients with critical lower limb ischaemia. Eur J Vasc Endovasc Surg 32 (2006) 51-59
99. Rosenblatt M.S., Quist W.C., Sidawy A.N., et al. Results of vein graft reconstruction of the lower extremity in diabetic and nondiabetic patients. Surg Gynecol Obstet 171 (1990) 331-335
100. Gahtan V., Harpavat M., Roberts A.B., et al. Impact of diabetes mellitus on infrainguinal bypass grafting. J Diabetes Complications 12 (1998) 197-200
101. Spence L.D., Hartnell G.G., Reinking G., et al. Diabetic versus nondiabetic limb-threatening ischemia: outcome of percutaneous iliac intervention. AJR Am J Roentgenol 172 (1999) 1335-1341
102. Maca T., Schillinger M., Hamwi A., et al. Insulin, C-peptide, and restenosis after femoral artery balloon angioplasty in type II diabetic and nondiabetic patients. J Vasc Interv Radiol 16 (2005) 31-35
103. Schillinger M., Exner M., Mlekusch W., et al. Endovascular revascularization below the knee: 6-month results and predictive value of C-reactive protein level. Radiology 227 (2003) 419-425
104. Sommeijer D.W., MacGillavry M.R., Meijers J.C., et al. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care 27 (2004) 468-473
105. van der Ree M.A., Huisman M.V., Princen H.M., et al. DALI-Study Group. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166 (2003) 129-135
106. Lee I.T., Sheu W.H., Lin S.Y., et al. Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. J Diabetes Complications 16 (2002) 382-385
107. Gazi I.F., and Mikhailidis D.P. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opin Ther Targets 10 (2006) 851-866
108. Shinohara K., Shoji T., Kimoto E., et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 12 (2005) 205-210
109. Youssef F., Gupta P., Seifalian A.M., et al. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 55 (2004) 53-62
110. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., et al. The effect of statins versus untreated dyslipidemia in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. J Clin Pathol 57 (2004) 728-734
111. Collins R., Armitage J., Parish S., et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
112. Mohler III E.R., Hiatt W.R., and Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003) 1481-1486
113. Giri J., McDermott M.M., Greenland P., et al. Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol 47 (2006) 998-1004
114. Hankey G.J., Norman P.E., and Eikelboom J.W. Medical treatment of peripheral arterial disease. JAMA 295 (2006) 547-553
115. Regensteiner J.G., and Stewart K.J. Established and evolving medical therapies for claudication in patients with peripheral arterial disease. Nat Clin Pract Cardiovasc Med 3 (2006) 604-610
116. Beaudry D., Stone K.E., Wetherold S., et al. Statin therapy in cardiovascular diseases other than atherosclerosis. Curr Atheroscler Rep 9 (2007) 25-32
117. Daskalopoulou S.S., Daskalopoulos M.E., Liapis C.D., et al. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem 12 (2005) 443-452
118. Erez G., and Leitersdorf E. The rationale for using HMG-CoA reductase inhibitors ("statins") in peripheral arterial disease. Eur J Vasc Endovasc Surg 33 (2007) 192-201
119. Rice T.W., and Lumsden A.B. Optimal medical management of peripheral arterial disease. Vasc Endovasc Surg 40 (2006) 312-327
120. Schillinger M., Exner M., Mlekusch W., et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 25 (2004) 742-748
121. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
122. Brown L.C., Johnson J.A., Majumdar S.R., et al. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 171 (2004) 1189-1192
123. Henke P.K., Blackburn S., Proctor M.C., et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 39 (2004) 357-365
124. Poon M., Badimon J.J., and Fuster V. Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. Lancet 359 (2002) 619-622
125. Dorffler-Melly J., Koopman M.M., Prins M.H., et al. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 1 (2005) CD002071
126. Schweizer J., Muller A., Forkmann L., et al. Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty. Angiology 52 (2001) 659-669
127. Girolami B., Bernardi E., Prins M.H., et al. Antiplatelet therapy and other interventions after revascularization procedures in patients with peripheral arterial disease: a meta-analysis. Eur J Vasc Endovasc Surg 19 (2000) 370-380
128. Holmes Jr. D.R., Savage M., LaBlanche J.M., et al. Results of Prevention of Restenosis with Tranilast and Its Outcomes (PRESTO) trial. Circulation 106 (2002) 1243-1250
129. Kutryk M.J., Foley D.P., van den Brand M., et al. ITALICS trial. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 39 (2002) 281-287
130. De Feyter P.J., Vos J., and Rensing B.J. Anti-restenosis trials. Curr Interv Cardiol Rep 2 (2000) 326-331
131. Gallo R., Padurean A., Jayaraman T., et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99 (1999) 2164-2170
132. Suzuki T., Kopia G., Hayashi S., et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104 (2001) 1188-1193
133. Marx S.O., and Marks A.R. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104 (2001) 852-855
134. Duda S.H., Pusich B., Richter G., et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 106 (2002) 1505-1509
135. Duda S.H., Bosiers M., Lammer J., et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results form the SIROCCO trial. J Endovasc Ther 13 (2006) 701-710
136. Kawasumi M., Tanaka Y., Uchino H., et al. Strict glycemic control ameliorates the increase of carotid IMT in patients with type 2 diabetes. Endocr J 53 (2006) 45-50
137. Therasse E., Donath D., Lesperance J., et al. External beam radiation to prevent restenosis after superficial femoral artery balloon angioplasty. Circulation 111 (2005) 3310-3315
138. Zabakis P., Kardamakis D.M., Siablis D., et al. External beam radiation therapy reduces the rate of re-stenosis in patients treated with femoral stenting: results of a randomised study. Radiother Oncol 74 (2005) 11-16
139. Zehnder T., von Briel C., Baumgartner I., et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. J Endovasc Ther 10 (2003) 304-311
140. Hansrani M., Overbeck K., Smout J., et al. Intravascular brachytherapy: a systematic review of its role in reducing restenosis after endovascular treatment in peripheral arterial disease. Eur J Vasc Endovasc Surg 24 (2002) 377-382
141. Nori D., Parikh S., and Moni J. Management of peripheral vascular disease: innovative approaches using radiation therapy. Int J Radiat Oncol Biol Phys 36 (1996) 847-856
142. Nakamura N., Hamazaki T., Johkaji H., et al. Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. Clin Exp Med 2 (2003) 180-184
143. Uchikawa T., Murakami T., and Furukawa H. Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneimittelforschung 42 (1992) 322-324
144. Robless P., Mikhailidis D., and Stansby G. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 1 (2007) CD003748
145. Douglas Jr. J.S., Holmes Jr. D.R., et al. Cilostazol for Restenosis Trial (CREST) Investigators: Coronary stent restenosis in patients treated with cilostazol. Circulation 112 (2005) 2826-2832
146. Paraskevas K.I., Liapis C.D., Hamilton G., et al. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?. Eur J Vasc Endovasc Surg 32 (2006) 286-293
147. Shammas N.W. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag 3 (2007) 229-234
148. Fatourou E.M., Paraskevas K.I., Seifalian A.M., et al. The role of established and emerging risk factors of peripheral arterial disease. Expert Opin Pharmacother 8 (2007) 901-911
149. Bianchi C., Montalvo V., Ou H.W., et al. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann Vasc Surg 21 (2007) 163-166
150. Brevetti G., Oliva G., Giugliano G., et al. Mortality in peripheral arterial disease: a comparison of patients managed by vascular specialists and general practitioners. J Gen Intern Med 22 (2007) 639-644
151. Wahlgren C.M., Kalin B., Lund K., et al. Long-term outcome of infrainguinal percutaneous transluminal angioplasty. J Endovasc Ther 11 (2004) 287-293
152. Kudo T., Chandra F.A., and Ahn S.S. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. J Vasc Surg 41 (2005) 423-435
153. Lazaris A.M., Salas C., Tsiamis A.C., et al. Factors affecting patency of subintimal infrainguinal angioplasty in patients with critical lower limb ischemia. Eur J Vasc Endovasc Surg 32 (2006) 668-674